Neoleukin Therapeutics, Inc. (NASDAQ:NLTX - Get Free Report) was down 5.8% on Wednesday . The company traded as low as $16.95 and last traded at $17.35. Approximately 141,373 shares were traded during trading, an increase of 182% from the average daily volume of 50,104 shares. The stock had previously closed at $18.42.
Neoleukin Therapeutics Stock Up 2.0 %
The company has a market cap of $162.68 million, a PE ratio of -5.57 and a beta of 1.11. The company's fifty day moving average is $19.80 and its 200-day moving average is $32.40.
About Neoleukin Therapeutics
(
Get Free Report)
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
See Also
Before you consider Neoleukin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neoleukin Therapeutics wasn't on the list.
While Neoleukin Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
